150 related articles for article (PubMed ID: 37883727)
21. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
22. Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Jabbour E; Haddad FG; Short NJ; Senapati J; Jain N; Sasaki K; Jorgensen J; Wang SA; Alvarado Y; Wang X; DiNardo C; Masarova L; Kadia T; Garris RS; Ravandi F; Kantarjian H
Blood; 2024 Feb; 143(5):417-421. PubMed ID: 37879077
[TBL] [Abstract][Full Text] [Related]
23. Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia.
Fischer D; Toenges R; Kiil K; Michalik S; Thalhammer A; Bug G; Gökbuget N; Lang F
Ann Hematol; 2024 Feb; 103(2):489-498. PubMed ID: 37999763
[TBL] [Abstract][Full Text] [Related]
24. Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Badar T; Szabo A; Wadleigh M; Liedtke M; Arslan S; Siebenaller C; Aldoss I; Schultz E; Hefazi M; Litzow MR; Kuo E; Wang A; Curran E; Shallis RM; Podoltsev N; Balasubramanian S; Yang J; Mattison R; Burkart M; Dinner S; Advani A; Atallah E
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):556-560.e2. PubMed ID: 32291234
[TBL] [Abstract][Full Text] [Related]
25. [Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia].
An LL; Zhao DF; Hou RF; Guan HH; Yan H; Lin YH; Tong CR; Wu T; Liu SY
Zhonghua Xue Ye Xue Za Zhi; 2023 Nov; 44(11):911-916. PubMed ID: 38185520
[No Abstract] [Full Text] [Related]
26. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
[TBL] [Abstract][Full Text] [Related]
27. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
Al-Salama ZT
Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
[TBL] [Abstract][Full Text] [Related]
28. [Relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia responding to retreatment with inotuzumab ozogamicin].
Hashimoto H; Tamura Y; Yamada K; Katoh Y; Shimada T; Fujiwara R; Hanamoto H
Rinsho Ketsueki; 2023; 64(8):746-750. PubMed ID: 37673626
[TBL] [Abstract][Full Text] [Related]
29. Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia.
Fujishima N; Uchida T; Onishi Y; Jung CW; Goh YT; Ando K; Wang MC; Ono C; Matsumizu M; Paccagnella ML; Sleight B; Vandendries E; Fujii Y; Hino M
Int J Hematol; 2019 Dec; 110(6):709-722. PubMed ID: 31655984
[TBL] [Abstract][Full Text] [Related]
30. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
George B; Kantarjian H; Jabbour E; Jain N
Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
[TBL] [Abstract][Full Text] [Related]
31. Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia.
Proskorovsky I; Su Y; Fahrbach K; Vandendries E; Pagé V; Onyekwere U; Wang Y; Cappelleri JC; Stelljes M
Adv Ther; 2019 Aug; 36(8):2147-2160. PubMed ID: 31140123
[TBL] [Abstract][Full Text] [Related]
32. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
33. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia.
Kantarjian H; Thomas D; Jorgensen J; Kebriaei P; Jabbour E; Rytting M; York S; Ravandi F; Garris R; Kwari M; Faderl S; Cortes J; Champlin R; O'Brien S
Cancer; 2013 Aug; 119(15):2728-36. PubMed ID: 23633004
[TBL] [Abstract][Full Text] [Related]
34. Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
Lee SH; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Int J Hematol; 2022 Jan; 115(1):135-139. PubMed ID: 34617186
[TBL] [Abstract][Full Text] [Related]
35. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
36. Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
O'Brien MM; Ji L; Shah NN; Rheingold SR; Bhojwani D; Yuan CM; Xu X; Yi JS; Harris AC; Brown PA; Borowitz MJ; Militano O; Kairalla J; Devidas M; Raetz EA; Gore L; Loh ML
J Clin Oncol; 2022 Mar; 40(9):956-967. PubMed ID: 35007127
[TBL] [Abstract][Full Text] [Related]
37. SOHO State of the Art Updates and Next Questions | Approach to Older Adults With Phildadelphia-Chromosome Negative Acute Lymphoblastic Leukemia.
Shimony S; Luskin MR
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):133-140. PubMed ID: 38102012
[TBL] [Abstract][Full Text] [Related]
38. Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
Ogura M; Tobinai K; Hatake K; Davies A; Crump M; Ananthakrishnan R; Ishibashi T; Paccagnella ML; Boni J; Vandendries E; MacDonald D
Clin Cancer Res; 2016 Oct; 22(19):4807-4816. PubMed ID: 27154915
[TBL] [Abstract][Full Text] [Related]
39. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study.
Kantarjian H; Thomas D; Jorgensen J; Jabbour E; Kebriaei P; Rytting M; York S; Ravandi F; Kwari M; Faderl S; Rios MB; Cortes J; Fayad L; Tarnai R; Wang SA; Champlin R; Advani A; O'Brien S
Lancet Oncol; 2012 Apr; 13(4):403-11. PubMed ID: 22357140
[TBL] [Abstract][Full Text] [Related]
40. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL.
Kirchhoff H; Karsli U; Schoenherr C; Battmer K; Erschow S; Talbot SR; Steinemann D; Heuser M; Heidenreich O; Hilfiker-Kleiner D; Ganser A; Eder M; Scherr M
Blood; 2021 May; 137(19):2657-2661. PubMed ID: 33512436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
